Table 3.

Second induction regimens frequency and response rates.

Second induction regimen	Frequency of utilization, n (%) (n = 376)	Response rates
		ORR, n (%)	≥VGPR, n (%)
CyBor-D/P	33 (8.8)	19 (57.6)	14 (42.4)
R/RD/RP	116 (30.9)	84 (72.4)	45 (38.8)
RVD/RVP	114 (30.3)	93 (81.6)	31 (27.2)
Other	38 (10.1)	20 (52.6)	7 (18.4)
V/VD	21 (5.6)	14 (66.7)	6 (28.6)
KRD	20 (5.3)	20 (100)	15 (75)
DaraRD	16 (4.3)	15 (93.8)	12 (75)
IxaRD	10 (2.7)	5 (50)	3 (30)
TC/TCD/TCP	8 (2.1)	4 (50)	0 (0)

CyBor-D/P cyclophosphamide + bortezomib + dexamethasone or prednisone, R lenalidomide, V bortezomib, K carfilzomib, Dara daratumumab, Ixa ixazomib, T thalidomide, C cyclophosphamide.